Cartesian Therapeutics Announces New Employment Inducement Grants
April 04 2024 - 7:00AM
Business Wire
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a
clinical-stage biotechnology company developing mRNA cell therapies
for the treatment of autoimmune diseases, today announced the
granting of inducement awards to four new employees. On April 1,
2024, the Company issued to each of these employees an option to
purchase shares of the Company’s common stock with an exercise
price of $0.5601, the closing trading price of the Company’s common
stock on the Nasdaq Global Market on the date of grant. The options
are exercisable for an aggregate of 765,000 shares of the Company’s
common stock. Each of the four options was granted pursuant to the
Company’s Amended and Restated 2018 Employment Inducement Incentive
Award Plan and was approved by the Company’s board of directors.
The options each vest as to 25% on April 1, 2025, and then in three
equal installments thereafter such that the option will be fully
vested on April 1, 2028. The options each have a ten-year term. The
options were granted under Rule 5635(c)(4) of the Nasdaq Listing
Rules as an inducement material to the employee’s entry into
employment with the Company.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company developing
mRNA cell therapies for the treatment of autoimmune diseases. The
Company’s lead asset, Descartes-08, is a potential first-in-class
mRNA CAR-T in Phase 2b clinical development for patients with
generalized myasthenia gravis. Additional Phase 2 studies are
planned in systemic lupus erythematosus under an allowed IND, as
well as basket trials in additional autoimmune indications. The
Company’s clinical-stage pipeline also includes Descartes-15, a
next-generation, autologous anti-BCMA mRNA CAR-T.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404459604/en/
Investor Relations: Melissa Forst Argot Partners
cartesian@argotpartners.com
Media: David Rosen Argot Partners
cartesian@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Dec 2023 to Dec 2024